T1	Participants 365 461	95 subjects enrolled in the United States Food and Drug Administration Phase III clinical trials
T2	Participants 471 547	At 1 year, 99% of patients (89 of 90) had 20/40 uncorrected vision or better
T3	Participants 549 586	Ninety-two percent of eyes (83 of 90)
